Serena X. Zhang, Maria Amoreth R. Gozo, Epiphany L. Nick, Martin Dittme, Ata S. Moshiri and Anna L. Cogen*
Leukocytoclastic vasculitis has been reported to occur in myleproliferative disorders as well as in the setting of medications. Anagrelide has been increasingly accepted as a non-inferior alternative platelet-lowering agent over hydroxyurea in the management of essential thrombocythemia. From a dermatologic standpoint, anagrelide leads to fewer skin toxicities compared to that of hydroxyurea, though exposure to both has been associated with the development of leg ulcers. Here, we report a case of biopsy-proven small and medium vessel vasculitis in a patient with essential thrombocythemia during treatment with anagrelide.
